Bharat Parenterals Ltd

Bharat Parenterals Ltd

Bharat Parenterals Ltd reported Q2FY27 earnings, with consolidated revenue up 110% YoY and 45% QoQ, EBITDA margin expanding by 800 basis points to 17.3%, and profit after tax at INR 11.8 crores. The company's Innoxel and Varenyam Healthcare platforms contributed 45% of revenue and 60% of EBITDA.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the audio recording of its Q2FY27 earnings conference call, hosted on its website for investor access.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has published unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, in compliance with Regulation 30 and 47 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced its Q2 FY27 results, showing a 110.9% YoY increase in revenue to ₹136.3 Cr, with EBITDA margin expanding to 19.2% and PAT turning positive at ₹11.8 Cr. The company's Innoxel business swung to a profit of ₹5.4 Cr, while BPL standalone gross margin eased to 34.8%.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced its un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company's revenue from operations for the quarter ended September 30, 2026, was Rs 7,855.44 lakhs, and the total income was Rs 8,150.81 lakhs.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with revenue from operations at Rs 7,855.44 lakhs and total income at Rs 8,150.81 lakhs.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has published a newspaper notice informing physical shareholders about a special window for re-lodging transfer requests for physical shares that were lodged prior to April 1, 2019, and rejected due to deficiencies in documents or process.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the approval of a preferential issue through an Extra-Ordinary General Meeting (EGM) held on October 23, 2026. The company submitted revised voting results to rectify an inadvertent categorisation error in the voting-results statement. The revised voting results were placed on the company's website and on the website of National Securities Depository Limited.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has submitted revised voting results for its EGM held on October 23, 2026, correcting an inadvertent categorization error in the voting results submitted earlier. The revision does not change the outcome of any resolutions or the number of votes cast.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced that its shareholders have approved the issuance of equity shares on a preferential basis and making investments, giving loans, guarantees, and providing security in excess of limits specified under Section 186(2) of the Companies Act, 2013.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the voting results and scrutinizer report for its EGM held on October 23, 2026, where two resolutions were passed with requisite majority, including the issuance of equity shares on a preferential basis and making investments, giving loans, guarantees, and providing security in excess of limits specified under Section 186(2) of the Companies Act, 2013.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced a Q2FY27 earnings conference call to discuss its operational and financial performance for the quarter and half year ended September 30, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has scheduled a Board meeting on October 29, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd held an Extra Ordinary General Meeting (EGM) on October 23, 2026, through video conferencing. The meeting was attended by 28 members, and the results of remote e-voting and e-voting during the EGM will be declared on the company's website within two working days. The meeting was declared in order, and the chairman briefed the members about the two proposals for approval: issuance of equity shares on a preferential basis and approval for making investments, giving loans, and providing security in excess of limits specified under Section 186(2) of the Companies Act, 2013.

Bharat Parenterals Ltd

Bharat Parenterals Ltd's subsidiary Innoxel Lifesciences Private Limited has commenced commercial supply to the United States, marking a shift from licensing income to recurring commercial supply. The first product manufactured by Innoxel under a contract manufacturing arrangement was launched in the U.S. market on October 20, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd publishes newspaper advertisements under Regulation 30 of SEBI LODR (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding proposed transfer of shares.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has submitted a copy of the newspaper advertisement dated October 14, 2026, informing shareholders about the dispatch of the corrigendum to the notice of EGM to be held on October 23, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has issued a corrigendum to the Extra-Ordinary General Meeting (EGM) notice, seeking approval for a proposed Preferential Issue of Equity Shares. The company has been directed by BSE to issue additional disclosures on the appointment of a Monitoring Agency.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the acceptance or rejection of securities received for dematerialization during the quarter ended September 30, 2026.

Bharat Parenterals Ltd

Bharat Parenterals Ltd has announced the newspaper publication for the 1st EGM of FY 2026-27, scheduled to be held on October 23, 2026, through video conferencing.